About PCI Biotech
PCI Biotech is a publicly listed company based in Oslo (Norway) founded in 2007. Novel cancer therapies are developed using photochemical internalization technology. The company has 5 employees. Its chief executive, as recorded, is Per Walday. PCI Biotech offers products and services including Viral Vector Manufacturing Technology and Intracellular Drug Delivery System. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is PCI Biotech Holding ASA.
Company details
PCI Biotech was founded in 2007 in Oslo, Norway, and operates within the biotechnology sector. Cancer treatments are developed through a proprietary photochemical internalization (PCI) platform, which facilitates endosomal release to enhance various therapeutic modalities. This technology supports three anticancer approaches: fimaCHEM for localized chemotherapeutic enhancement, fimaVACC for T-cell induction in vaccination, and fimaNAC for nucleic acid delivery.
- Headquarters Oslo, Norway
- Employees 5
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website pcibiotech.no
- Legal Name Pci Biotech Holding Asa
- Net Profit-$1.45 M (USD)19.19as on Dec 31, 2024
- EBITDA-$2.15 M (USD)1.9as on Dec 31, 2024
- Employee Count5
Products & Services of PCI Biotech
PCI Biotech offers a comprehensive portfolio of products and services, including Viral Vector Manufacturing Technology and Intracellular Drug Delivery System.
Technology for advancing viral vector production in bioprocessing applications.
System for targeted drug delivery in immunotherapy and dermatology.
People of PCI Biotech
8 people are tracked at PCI Biotech (5 in leadership, 3 in board & advisors); the tracked headcount is 5.
| Name | Role | Group |
|---|---|---|
Per Walday | CEO | Leadership |
Kristin Eivindvik | Chief Development Officer | Leadership |
Morten Luhr | Chief Scientific Officer | Leadership |
Ronny Skuggedal | CEO PCI Biotech Holding ASA | Leadership |
Anders Høgset | Chief Scientific Officer | Leadership |
Hilde Furberg | Board Member | Board & advisors |
Lars Viksmoen | Board Member | Board & advisors |
Hans Peter Bøhn | Chairman | Board & advisors |
Complete people profiles for PCI Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of PCI Biotech
PCI Biotech is a publicly listed company on the OSL with ticker symbol PCIB in Norway, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Jun 2008
- Listed onEuronext: PCIB
- Listed entityPCI Biotech Holding ASA
- Exchange sectorHealth technology
- ISINNO0010405640
- Share price0.08 NOK (-30.43% on the day) · 2026-04-23
- Market capitalisation4,292,535.00 NOK
- Volume (last session)1,040,607
- Analyst consensusNo rating
Financials of PCI Biotech
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -16.4M NOK | -24.4M NOK | |
| 2023 | -20.3M NOK | -24.9M NOK | |
| 2022 | -55.1M NOK | -60.6M NOK | |
| 2021 | -88.4M NOK | -89.8M NOK | |
| 2020 | -72.2M NOK | -87.3M NOK |
Detailed financial statements for PCI Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of PCI Biotech
The website of PCI Biotech (pcibiotech.no) receives about 1.8K visits a month and ranks #6,553,934 among all websites worldwide, #6,637 in Biotechnology and Pharmaceuticals.
- Monthly visits1.8K
▼ 28.8% vs previous month
- Unique visitors1.1K
per month
- Global rank#6,553,934
among all websites
- Category rank#6,637
Health · Biotechnology and Pharmaceuticals
- Bounce rate32%
- Pages per visit1.5
- Average visit22 sec
- DevicesDesktop 14% · Mobile 86%
Websites whose visitors overlap most with PCI Biotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hearingreview.com | 100% | #694,055 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pci Biotech
Complete news archive for PCI Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PCI Biotech
PCI Biotech was founded in 2007.
PCI Biotech is headquartered in Oslo, Norway. It is registered at Oslo, Oslo, Norway.
Per Walday is the CEO of PCI Biotech, as recorded in our data.
PCI Biotech has 5 employees.
PCI Biotech was founded in 2007 in Oslo, Norway, and operates within the biotechnology sector. Cancer treatments are developed through a proprietary photochemical internalization (PCI) platform, which facilitates endosomal release to enhance various therapeutic modalities. This technology supports three anticancer approaches: fimaCHEM for localized chemotherapeutic enhancement, fimaVACC for T-cell induction in vaccination, and fimaNAC for nucleic acid delivery.
PCI Biotech offers Viral Vector Manufacturing Technology and Intracellular Drug Delivery System.
Yes, PCI Biotech is publicly traded on OSL under the ticker symbol PCIB.
PCI Biotech operates through Pci Biotech Holding Asa.